STOCK TITAN
  1. Home
  2. SEC Filings
  3. LYCA
  4. [Form 4] Lycia Therapeutics, Inc. Insider Trading Activity

Lycia Therapeutics: Venrock funds buy 2.05M shares

Preferred shares also converted into common shares when Lycia's initial public offering closed on October 26, 2026.

Filing Impact
(High)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
4

Rhea-AI Filing Summary

Lycia Therapeutics, Inc. reported that Venrock-associated funds purchased 2,045,440 common shares across October 23, October 26 and October 27, 2026. This included 1,944,444 shares at $18.00 per share on October 26; the five other purchases were reported at weighted-average prices of $25.68, $26.11, $26.97, $25.84 and $26.84 per share.

On October 26, 17,142,578 Series C and 4,408,091 Series D preferred shares automatically converted into 3,802,108 and 977,685 common shares, respectively, without payment of consideration, upon the closing of Lycia's initial public offering, on a one-for-0.221793422 basis. Bong Y. Koh and Nimish P. Shah, identified as 10% owners and voting members of fund managers, may be deemed beneficial owners of fund-held shares; they disclaim beneficial ownership except to the extent of indirect pecuniary interests.

Insights

Analyzing...

Insider Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management EG, LLC, Venrock Healthcare Capital Partners XP, L.P., VHCP Management XP, LLC, Koh Bong Y, Shah Nimish P
Role 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Bought 2,045,440 shs ($37.65M)
Type Security Shares Price Value
Purchase Common Stock F17, F18, F19, F3, F4, F11 8,729 $25.84 $226K
Purchase Common Stock F20, F21, F22, F3, F4, F11 31,067 $26.84 $834K
Conversion Series C Preferred Stock F9, F23, F24, F3, F4 17,142,578 $0.00 $0.00
Conversion Series D Preferred Stock F9, F25, F26, F4, F11 4,408,091 $0.00 $0.00
Conversion Common Stock F8, F9, F10, F3, F4, F11 4,779,793 -- --
Purchase Common Stock F12, F13, F3, F4, F11 1,944,444 $18.00 $35.00M
Purchase Common Stock F14, F15, F16, F3, F4, F11 8,261 $26.97 $223K
Purchase Common Stock F1, F2, F3, F4 24,560 $25.68 $631K
Purchase Common Stock F5, F6, F7, F3, F4 28,379 $26.11 $741K
Holdings After Transaction: Series C Preferred Stock — 0 contracts (Indirect, By Funds); Series D Preferred Stock — 0 contracts (Indirect, By Funds); Common Stock — 6,825,233 shares (Indirect, By Funds)
Footnotes (26)
  1. F1. Consists of (i) 11,163 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 1,118 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 12,279 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
  2. F2. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.00 to $25.99 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  3. F3. VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own the shares held by VHCP3 and VHCP Co-3. Bong Koh and Nimish Shah are the voting members of VHCPM3 and may be deemed to beneficially own these shares. Each of VHCPM3 and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
  4. F4. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCP EG and may be deemed to beneficially own the shares held by VHCP EG. Bong Koh and Nimish Shah are the voting members of VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
  5. F5. Consists of (i) 12,898 shares held by VHCP3; (ii) 1,292 shares held by VHCP Co-3; and (iii) 14,189 shares held by VHCP EG.
  6. F6. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.00 to $26.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  7. F7. Consists of (i) 24,061 shares held by VHCP3; (ii) 2,410 shares held by VHCP Co-3; and (iii) 26,468 shares held by VHCP EG.
  8. F8. Consists of (i) 828,479 shares held by VHCP3; (ii) 82,885 shares held by VHCP Co-3; (iii) 3,216,639 shares held by VHCP EG; and (iv) 651,790 shares held by Venrock Healthcare Capital Partners XP, L.P. ("VHCP XP").
  9. F9. Each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.221793422 basis upon the closing of the Issuer's initial public offering on October 26, 2026 without payment of consideration. The Series C Preferred Stock and Series D Preferred Stock had no expiration date.
  10. F10. Consists of (i) 852,540 shares held by VHCP3; (ii) 85,295 shares held by VHCP Co-3; (iii) 3,243,107 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
  11. F11. VHCP Management XP, LLC ("VHCPMXP") is the general partner of VHCP XP and may be deemed to beneficially own the shares held by VHCP XP. Bong Koh and Nimish Shah are the voting members of VHCPMXP and may be deemed to beneficially own these shares. Each of VHCPMXP and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
  12. F12. Consists of (i) 883,750 shares held by VHCP3; (ii) 88,472 shares held by VHCP Co-3; and (iii) 972,222 shares held by VHCP EG.
  13. F13. Consists of (i) 1,736,290 shares held by VHCP3; (ii) 173,767 shares held by VHCP Co-3; (iii) 4,215,329 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
  14. F14. Consists of (i) 3,755 shares held by VHCP3; (ii) 376 shares held by VHCP Co-3; and (iii) 4,130 shares held by VHCP EG.
  15. F15. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.82 to $27.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  16. F16. Consists of (i) 1,740,045 shares held by VHCP3; (ii) 174,143 shares held by VHCP Co-3; (iii) 4,219,459 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
  17. F17. Consists of (i) 3,967 shares held by VHCP3; (ii) 397 shares held by VHCP Co-3; and (iii) 4,365 shares held by VHCP EG.
  18. F18. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.28 to $26.27 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  19. F19. Consists of (i) 1,744,012 shares held by VHCP3; (ii) 174,540 shares held by VHCP Co-3; (iii) 4,223,824 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
  20. F20. Consists of (i) 14,120 shares held by VHCP3; (ii) 1,414 shares held by VHCP Co-3; and (iii) 15,533 shares held by VHCP EG.
  21. F21. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.28 to $27.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  22. F22. Consists of (i) 1,758,132 shares held by VHCP3; (ii) 175,954 shares held by VHCP Co-3; (iii) 4,239,357 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
  23. F23. Consists of (i) 3,735,368 shares held by VHCP3; (ii) 373,708 shares held by VHCP Co-3; and (iii) 13,033,502 shares held by VHCP EG.
  24. F24. Consists of (i) 828,479 shares held by VHCP3; (ii) 82,885 shares held by VHCP Co-3; and (iii) 2,890,744 shares held by VHCP EG.
  25. F25. Consists of (i) 1,469,363 shares held by VHCP EG and (ii) 2,938,728 shares held by VHCP XP.
  26. F26. Consists of (i) 325,895 shares held by VHCP EG and (ii) 651,790 shares held by VHCP XP.
Common shares purchased 2,045,440 shares Six purchases on October 23, October 26 and October 27, 2026
Purchase at $18.00 per share 1,944,444 shares at $18.00 per share October 26, 2026
Series C Preferred Stock converted 17,142,578 shares Automatic conversion on October 26, 2026
Series D Preferred Stock converted 4,408,091 shares Automatic conversion on October 26, 2026
Common shares from preferred-stock conversion 4,779,793 shares October 26, 2026
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficial ownership regulatory
"expressly disclaims beneficial ownership over these shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
indirect pecuniary interest financial
"except to the extent of its or his indirect pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LYCA shares did Venrock-associated funds buy?
Venrock-associated funds reported purchases of 2,045,440 common shares in six transactions on October 23, October 26 and October 27, 2026. One purchase was 1,944,444 shares at $18.00 per share on October 26. The other five reported prices were weighted averages. No Rule 10b5-1 plan is reported.

How many LYCA common shares came from the preferred-stock conversion?
The October 26, 2026 conversion produced 3,802,108 common shares from Series C Preferred Stock and 977,685 from Series D Preferred Stock. The preferred shares automatically converted without payment of consideration upon the closing of Lycia's initial public offering, on a one-for-0.221793422 basis.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Available on EDGAR Accepted by SEC EDGAR
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Venrock Healthcare Capital Partners III, L.P.
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Lycia Therapeutics, Inc. [ LYCA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
10/23/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock10/23/2026P24,560(1)A$25.68(2)24,560(1)IBy Funds(3)(4)
Common Stock10/23/2026P28,379(5)A$26.11(6)52,939(7)IBy Funds(3)(4)
Common Stock10/26/2026C4,779,793(8)A(9)4,832,732(10)IBy Funds(3)(4)(11)
Common Stock10/26/2026P1,944,444(12)A$186,777,176(13)IBy Funds(3)(4)(11)
Common Stock10/26/2026P8,261(14)A$26.97(15)6,785,437(16)IBy Funds(3)(4)(11)
Common Stock10/27/2026P8,729(17)A$25.84(18)6,794,166(19)IBy Funds(3)(4)(11)
Common Stock10/27/2026P31,067(20)A$26.84(21)6,825,233(22)IBy Funds(3)(4)(11)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Series C Preferred Stock(9)10/26/2026C17,142,578(23) (9) (9)Common Stock3,802,108(24)$00IBy Funds(3)(4)
Series D Preferred Stock(9)10/26/2026C4,408,091(25) (9) (9)Common Stock977,685(26)$00IBy Funds(4)(11)
1. Name and Address of Reporting Person*
Venrock Healthcare Capital Partners III, L.P.
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
VHCP Co-Investment Holdings III, LLC
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
VHCP Management III, LLC
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Venrock Healthcare Capital Partners EG, L.P.
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
VHCP Management EG, LLC
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Venrock Healthcare Capital Partners XP, L.P.
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
VHCP Management XP, LLC
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Koh Bong Y
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Shah Nimish P
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. Consists of (i) 11,163 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 1,118 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 12,279 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
2. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.00 to $25.99 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
3. VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own the shares held by VHCP3 and VHCP Co-3. Bong Koh and Nimish Shah are the voting members of VHCPM3 and may be deemed to beneficially own these shares. Each of VHCPM3 and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
4. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCP EG and may be deemed to beneficially own the shares held by VHCP EG. Bong Koh and Nimish Shah are the voting members of VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
5. Consists of (i) 12,898 shares held by VHCP3; (ii) 1,292 shares held by VHCP Co-3; and (iii) 14,189 shares held by VHCP EG.
6. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.00 to $26.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
7. Consists of (i) 24,061 shares held by VHCP3; (ii) 2,410 shares held by VHCP Co-3; and (iii) 26,468 shares held by VHCP EG.
8. Consists of (i) 828,479 shares held by VHCP3; (ii) 82,885 shares held by VHCP Co-3; (iii) 3,216,639 shares held by VHCP EG; and (iv) 651,790 shares held by Venrock Healthcare Capital Partners XP, L.P. ("VHCP XP").
9. Each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.221793422 basis upon the closing of the Issuer's initial public offering on October 26, 2026 without payment of consideration. The Series C Preferred Stock and Series D Preferred Stock had no expiration date.
10. Consists of (i) 852,540 shares held by VHCP3; (ii) 85,295 shares held by VHCP Co-3; (iii) 3,243,107 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
11. VHCP Management XP, LLC ("VHCPMXP") is the general partner of VHCP XP and may be deemed to beneficially own the shares held by VHCP XP. Bong Koh and Nimish Shah are the voting members of VHCPMXP and may be deemed to beneficially own these shares. Each of VHCPMXP and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
12. Consists of (i) 883,750 shares held by VHCP3; (ii) 88,472 shares held by VHCP Co-3; and (iii) 972,222 shares held by VHCP EG.
13. Consists of (i) 1,736,290 shares held by VHCP3; (ii) 173,767 shares held by VHCP Co-3; (iii) 4,215,329 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
14. Consists of (i) 3,755 shares held by VHCP3; (ii) 376 shares held by VHCP Co-3; and (iii) 4,130 shares held by VHCP EG.
15. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.82 to $27.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
16. Consists of (i) 1,740,045 shares held by VHCP3; (ii) 174,143 shares held by VHCP Co-3; (iii) 4,219,459 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
17. Consists of (i) 3,967 shares held by VHCP3; (ii) 397 shares held by VHCP Co-3; and (iii) 4,365 shares held by VHCP EG.
18. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.28 to $26.27 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
19. Consists of (i) 1,744,012 shares held by VHCP3; (ii) 174,540 shares held by VHCP Co-3; (iii) 4,223,824 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
20. Consists of (i) 14,120 shares held by VHCP3; (ii) 1,414 shares held by VHCP Co-3; and (iii) 15,533 shares held by VHCP EG.
21. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.28 to $27.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
22. Consists of (i) 1,758,132 shares held by VHCP3; (ii) 175,954 shares held by VHCP Co-3; (iii) 4,239,357 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
23. Consists of (i) 3,735,368 shares held by VHCP3; (ii) 373,708 shares held by VHCP Co-3; and (iii) 13,033,502 shares held by VHCP EG.
24. Consists of (i) 828,479 shares held by VHCP3; (ii) 82,885 shares held by VHCP Co-3; and (iii) 2,890,744 shares held by VHCP EG.
25. Consists of (i) 1,469,363 shares held by VHCP EG and (ii) 2,938,728 shares held by VHCP XP.
26. Consists of (i) 325,895 shares held by VHCP EG and (ii) 651,790 shares held by VHCP XP.
Venrock Healthcare Capital Partners III, L.P., By: VHCP Management III, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory10/27/2026
VHCP Co-Investment Holdings III, LLC, By: VHCP Management III, LLC, Its: Manager, By: /s/ Sherman G. Souther, Authorized Signatory10/27/2026
VHCP Management III, LLC, By: /s/ Sherman G. Souther, Authorized Signatory10/27/2026
Venrock Healthcare Capital Partners EG, L.P., By: VHCP Management EG, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory10/27/2026
VHCP Management EG, LLC, By: /s/ Sherman G. Souther, Authorized Signatory10/27/2026
Venrock Healthcare Capital Partners XP, L.P., By: VHCP Management XP, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory10/27/2026
VHCP Management XP, LLC, By: /s/ Sherman G. Souther, Authorized Signatory10/27/2026
Bong Y. Koh, By: /s/ Sherman G. Souther, Attorney-in-Fact10/27/2026
Nimish P. Shah, By: /s/ Sherman G. Souther, Attorney-in-Fact10/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on LYCA

All LYCA news

Trending in the feed

JELD
JELD-WEN Announces Commencement of Exchange Offer and Consent Solicitation for Outstanding 4.875% Senior Notes due 2027 Open the live feed